uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Stockholm South Gen Hosp, Dept Oncol, Stockholm, Sweden..
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden..
Vise andre og tillknytning
2018 (engelsk)Inngår i: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 168, nr 2, s. 349-355Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C). Women aged 18-65 years, ECOG PS 0-1 with at least one positive axillary lymph node were randomized 1:1:1. The primary endpoint of the study was the safety and feasibility of the treatment. Toxicity was graded according to CTC-AE version 3.0. The design and short-term toxicity have been previously published. Here, we report safety and efficacy data after 10 years of follow-up. A total of 124 patients were included in the study. After a median follow-up of 10.3 years, the probability for 10-year survival was 78.5, 75.1, and 63.4% and for relapse free survival 64.1, 71.0, and 59.5% for groups A, B, and C, respectively. There were no cases of clinically diagnosed cardiotoxicity or hematologic malignancies. No patient was lost to follow-up. In this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10 years.

sted, utgiver, år, opplag, sider
SPRINGER , 2018. Vol. 168, nr 2, s. 349-355
Emneord [en]
Adjuvant chemotherapy, Breast cancer, Dose-dense, Randomized, Tailored dose
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-350272DOI: 10.1007/s10549-017-4599-4ISI: 000426778200006PubMedID: 29190004OAI: oai:DiVA.org:uu-350272DiVA, id: diva2:1205402
Forskningsfinansiär
Swedish Cancer SocietyKing Gustaf V Jubilee FundThe Karolinska Institutet's Research FoundationSwedish Research CouncilStockholm County CouncilTilgjengelig fra: 2018-05-14 Laget: 2018-05-14 Sist oppdatert: 2018-05-14bibliografisk kontrollert

Open Access i DiVA

fulltext(1023 kB)9 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1023 kBChecksum SHA-512
12436d13cb057b2b6fd685079227df6b4c5c08286678482fe658caa3136c4047d0583e4ebbbc0b1c9a683bf301599986b0ad07e2cb091801907ee82bc45cbc0d
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Lindman, Henrik

Søk i DiVA

Av forfatter/redaktør
Lindman, Henrik
Av organisasjonen
I samme tidsskrift
Breast Cancer Research and Treatment

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 9 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 48 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf